Last reviewed · How we verify
Calblock (AZELNIDIPINE)
Calblock (generic name: AZELNIDIPINE) is a azelnidipine drug. It is currently in Phase 3 development for Hypertensive disorder.
Calblock works by blocking calcium channels in blood vessel walls, which helps to relax the vessels and lower blood pressure.
Calblock (azelnidipine) is a small molecule drug that targets voltage-gated L-type calcium channels. It is used to treat hypertensive disorders by relaxing blood vessels and reducing blood pressure. The commercial status of Calblock is unknown, and it may be patented or have generic manufacturers. Key safety considerations include potential interactions with other medications and monitoring of blood pressure. Calblock is not FDA-approved, but it is approved in other countries for its indicated use.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AZELNIDIPINE |
|---|---|
| Drug class | azelnidipine |
| Target | Voltage-gated L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Imagine your blood vessels are like roads in your body. When calcium channels are open, they allow calcium to flow in and cause the roads to narrow and get congested. Calblock blocks these channels, allowing the roads to relax and widen, which helps to reduce blood pressure.
Approved indications
- Hypertensive disorder
Common side effects
- Cerebral infarction
- Hepatic function abnormal
- Renal impairment
- Cardiac failure
- Platelet count decreased
- Interstitial lung disease
Key clinical trials
- Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J) (PHASE4)
- Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients (PHASE4)
- Effects of Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea (OSA) (NA)
- Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study) (PHASE4)
- OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study (PHASE4)
- The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calblock CI brief — competitive landscape report
- Calblock updates RSS · CI watch RSS
Frequently asked questions about Calblock
What is Calblock?
How does Calblock work?
What is Calblock used for?
What is the generic name of Calblock?
What drug class is Calblock in?
What development phase is Calblock in?
What are the side effects of Calblock?
What does Calblock target?
Related
- Drug class: All azelnidipine drugs
- Target: All drugs targeting Voltage-gated L-type calcium channel
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertensive disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing